Produktbeschreibung
CPB519 is a 1+1 bivalent bispecific engineered to simultaneously target mouse CD3 and mouse or human TYRP1/TRP1 (gp75). CPB519 contains the murine IgG2a constant region to reduce immunogenicity and the formation of anti-drug antibodies (ADAs) in mouse models and LALA-PG Fc-silencing mutations to abolish antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) while minimizing Fc-driven off-target toxicity and depletion of checkpoint-expressing effector T cells. This bispecific is designed as a TRP1-directed CD3 T-cell engager to promote the activation and recruitment of cytotoxic T-cells to cells expressing murine or human TRP1, resulting in T-cell -mediated killing of TRP1+ cells.
* MwSt. und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
